What is the appropriate dosage of fluconazole (Diflucan) for a moderate vaginal yeast infection?

Fluconazole 150 mg as a single oral dose is the recommended treatment for moderate vaginal yeast infection

For a moderate (uncomplicated) vaginal yeast infection, the standard treatment is fluconazole 150 mg taken orally as a single dose 1, 2. This recommendation comes directly from the 2021 CDC STI Treatment Guidelines and FDA labeling, representing the current standard of care.

Understanding "Moderate" vs "Complicated" Infection

The term "moderate" typically falls under what guidelines classify as uncomplicated vulvovaginal candidiasis (VVC). This includes:

• Mild to moderate symptoms (itching, discharge, irritation)
• Infrequent episodes (not recurrent)
• Likely Candida albicans infection
• Normal immune function
• Non-pregnant patients

1

Dosing Details

Single-dose regimen:

• 150 mg fluconazole orally, one time only
• Can be taken with or without food
• No loading dose needed for vaginal candidiasis
• Peak plasma levels occur 1-2 hours after administration

2

Expected Outcomes

Clinical studies demonstrate excellent efficacy with this single-dose approach:

• 74-95% therapeutic cure rate at 28 days post-treatment
• 81-86% clinical cure (resolution of symptoms)
• 73-93% mycological eradication (negative cultures)
• Symptoms typically resolve within several days

3, 4, 5, 6

Alternative Options (If Fluconazole Unavailable or Contraindicated)

If oral fluconazole cannot be used, topical azole therapy is equally effective 1:

• Miconazole 200 mg vaginal suppository for 3 days
• Clotrimazole 2% cream 5g intravaginally for 3 days
• Terconazole 0.8% cream 5g intravaginally for 3 days

Critical Pitfalls to Avoid

Do not use fluconazole if:

• Patient is pregnant (use topical azoles only)
• Patient has severe renal impairment without dose adjustment
• Patient is taking medications with significant drug interactions (certain anticoagulants, some antiarrhythmics)

2

Consider treatment failure if:

• Symptoms persist beyond 7 days—obtain culture to identify non-albicans species or fluconazole resistance
• Fluconazole-resistant C. albicans is emerging (7.3% prevalence in one referral center), requiring alternative therapy like boric acid or oteseconazole 7
• Patient has recurrent VVC (≥4 episodes/year)—requires extended maintenance therapy, not just single-dose treatment

When Single-Dose Is NOT Sufficient

Do not use single-dose fluconazole for complicated VVC, which includes:

• Severe symptoms (extensive vulvar erythema, edema, excoriation)
• Recurrent infections (≥4 episodes per year)
• Non-albicans species (especially C. glabrata)
• Uncontrolled diabetes
• Immunocompromised patients
• Pregnancy

These situations require longer treatment courses (7-14 days of topical therapy or multiple doses of fluconazole) 1.

Patient Preference Data

When given the choice, 88% of patients prefer single-dose oral fluconazole over intravaginal therapy due to convenience and ease of use 5. This high patient satisfaction translates to better adherence and outcomes in real-world practice.